Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502811 · ClinicalTrials.gov registry record
The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices
A clinical trial of Mitral Regurgitation and Mitral Valve Regurgitation, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- 1,041
- Enrollment target
- 20
- Study locations
NCT03502811: Completed study of Mitral Regurgitation and Mitral Valve Regurgitation, sponsored by Abbott Medical Devices.
NCT03502811 is a study of Mitral Regurgitation and Mitral Valve Regurgitation that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,041 participants, roughly in line with the 984-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03502811, a study of Mitral Regurgitation and Mitral Valve Regurgitation, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- 1,041 participants
- Enrollment target
- 20
- Study locations
Study Summary
The MitraClip EXPAND Study (A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip Devices) is designed to confirm the safety and performance of the MitraClip NTR System and MitraClip XTR System.
Primary Outcome
MAE was defined as a composite of all-cause Death, Myocardial Infarction, Stroke, or non-elective Cardiovascular (CV) surgery for device related complications (CEC adjudicated).
Conditions Studied
Interventions
- DEVICE MitraClip NTR/XTR System
Study Locations (20)
California
- Scripps Health - La Jolla
- Cedars-Sinai Medical Center - Los Angeles
- University of California - Davis Medical Center - Sacramento
New York
- New York-Presbyterian/Columbia University Medical Center - New York
- Mount Sinai Hospital - New York
- New York University Hospital - New York
Alabama
- Baptist Medical Center Princeton - Birmingham
Arizona
- Phoenix Cardiovascular Research Group - Phoenix
Colorado
- University of Colorado Hospital - Aurora
Florida
- JFK Medical Center - West Palm Beach
Illinois
- Northwestern Memorial Hospital - Chicago
Kansas
- Via Christi Regional Medical Center - St. Francis Campus - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,041 participants |
| Start Date | 2018-04-26 |
| Est. Completion | 2020-12-31 |
What the finished NCT03502811 record still lists
NCT03502811 is an observational study that tracks outcomes without assigning an intervention. Its 1,041 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 984-participant average among 26 other Mitral Regurgitation trials with a reported enrollment target.
The record links to 2 conditions, with Mitral Regurgitation appearing as the primary indexed condition, and to 1 intervention - of which MitraClip NTR/XTR System is the first listed.
NCT03502811 names 20 study sites across 16 states, led by California, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT03502811 about?
NCT03502811 is a clinical study titled "The MitraClip® EXPAND Study of the Next Generation of MitraClip® Devices". The MitraClip EXPAND Study (A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip Devices) is designed to confirm the safety and performance of the MitraClip NTR System and MitraClip XTR System.
What is the current status of trial NCT03502811?
This trial is currently completed. The enrollment target is 1,041 participants. The study started on 2018-04-26. Estimated completion is 2020-12-31.
What conditions does trial NCT03502811 study?
This clinical trial studies the following conditions: Mitral Regurgitation, Mitral Valve Regurgitation.
What interventions are being tested in trial NCT03502811?
The interventions under investigation include: MitraClip NTR/XTR System (DEVICE).
Who is sponsoring clinical trial NCT03502811?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03502811 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitral Regurgitation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03502811's enrollment target sits among peer trials
1,041 6th of 26 higher than 21 of 26 other Mitral Regurgitation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mitral Regurgitation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System
RECRUITING · NA
-
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
RECRUITING · NA
-
EFS of the CardioMech MVRS
RECRUITING · NA
-
Annuloplasty Rings and Band Post-Market Clinical Follow-Up Study
RECRUITING
-
Novel Characterization of Sex Specific Biologic Signatures in Valvular Heart Disease
RECRUITING
-
In Search of Best Practices for Patients With Heart Failure and Secondary Mitral Regurgitation: An Evaluation of the Inova Heart Failure Treatment Algorithm
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI